• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Virbac (ENXTPA:VIRP) Reaffirmed 2026 Guidance, Is The Stock Still Cheap?

    Simply Wall St·10/31/2026 07:25:58
    Listen to the news

    Virbac (ENXTPA:VIRP) just reaffirmed its 2026 earnings guidance at the upper end of its initial revenue growth range after reporting higher unaudited sales for both the third quarter and the nine month period.

    Virbac shares trade at €347.0 after a 1 month share price return of 11.40%, while the 1 year total shareholder return is slightly down 1.68%. This suggests that near term momentum has picked up even though longer term performance has been mixed.

    Scan how Virbac compares to other potential breakout opportunities by reviewing the hand picked 199 high quality undervalued stocks built around quality fundamentals and compressed valuations.

    Virbac now trades well below both its estimated fair value and the average analyst target after this guidance lift and share price bounce. Is the discount compensation for real risk, or is it a market overreaction to past volatility?

    Most Popular Narrative: 16% Undervalued

    Against Virbac's last close at €347, the most followed narrative points to a fair value of €410.75. This frames the current pricing gap as meaningful rather than marginal.

    The main thing that has to go right is that Virbac converts heavy multi-year industrial and petfood capacity investment, expanded omnichannel and direct-to-consumer efforts, and the current pipeline of R&D and licensing projects into sustained, higher-margin growth without eroding returns through cost inflation or execution setbacks.

    See why 6 investors see Virbac as 16% undervalued.

    Result: Fair Value of €410.75 (UNDERVALUED)

    Still, elevated CapEx around €100m a year and ongoing foreign exchange headwinds on revenue and EBIT could easily knock this Virbac narrative off course.

    Find out about the key risks to this Virbac narrative.

    Next Steps

    Sentiment around Virbac in this article has leaned cautiously optimistic, so do not just take that at face value. Instead, move quickly and stress test the numbers yourself by checking the 4 key rewards.

    Looking for more investment ideas beyond Virbac?

    If you only stop at Virbac, you could miss other setups that fit your style just as well. Use the screeners below to broaden your opportunity set.